Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL versus LYGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL versus LYGEN.
LEVONORGESTREL AND ETHINYL ESTRADIOL vs LYGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and provides feedback inhibition on the hypothalamic-pituitary-ovarian axis, preventing follicular development and ovulation.
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
Oral, 1 tablet daily containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol, or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, taken at the same time each day for 21 days followed by 7 placebo tablets, or continuous daily dosing as per product labeling.
For adults, administer 500 mg orally twice daily with or without food.
None Documented
None Documented
Levonorgestrel: terminal half-life approximately 24-32 hours. Ethinyl estradiol: terminal half-life approximately 13-27 hours (mean ~17 hours). The half-lives are relevant for once-daily dosing, achieving steady state within 5-7 days.
12 hours; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min)
Levonorgestrel and ethinyl estradiol are primarily eliminated via renal excretion (40-68% as metabolites) and fecal excretion (20-45%). Less than 1% is excreted unchanged.
Renal (90% as unchanged drug), biliary/fecal (10%)
Category D/X
Category C
Estrogen
Estrogen